Please login to the form below

Not currently logged in
Email:
Password:

Genzyme wins Scottish approval for Renvela

Genzyme UK can supply Renvela within NHS Scotland after securing Scottish Medicine Consortium approval

Genzyme UK, a subsidiary of sanofi-aventis group, has received approval from the Scottish Medicine Consortium (SMC) to use Renvela within NHS Scotland as a treatment for hyperphosphataemia in adult patients with chronic kidney disease (CKD).

Renvela is a medication for the control of serum phosphorous in patients with CKD. Kidney failure causes levels of phosphate to rise in the blood, as the patient's kidneys are not able to excrete excess phosphate into the urine. Phosphorous build up is also associated with calcification of certain vessels.

Dr Alan Jardine, professor of renal medicine and head of the undergraduate medical school at University of Glasgow, said: "The availability of Renvela offers an efficacious addition to this class of agent, where existing therapies may have limited efficacy and poor patient compliance."

13th April 2011

From: Healthcare

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics